US 12,274,727 B2
Cannabigerol (CBG) products and methods of use
Michael Elzufon, Maple Grove, MN (US); and Howard Hoffberg, Reisterstown, MD (US)
Assigned to Bzelet Health Systems, Inc., Orlando, FL (US)
Filed by Bazelet Health Systems, Inc., Orlando, FL (US)
Filed on Feb. 5, 2024, as Appl. No. 18/433,252.
Application 18/433,252 is a division of application No. 17/990,637, filed on Nov. 18, 2022, granted, now 11,890,311, issued on Feb. 5, 2024.
Claims priority of provisional application 63/280,865, filed on Nov. 18, 2021.
Prior Publication US 2024/0180987 A1, Jun. 6, 2024
Int. Cl. A61K 36/185 (2006.01); A61K 31/00 (2006.01); A61K 31/05 (2006.01); A61K 31/12 (2006.01); A61K 31/16 (2006.01); A61K 31/164 (2006.01); A61K 31/165 (2006.01); A61K 31/19 (2006.01); A61K 31/4525 (2006.01); A61K 31/5685 (2006.01); A61K 36/068 (2006.01); A61K 36/28 (2006.01); A61K 36/9066 (2006.01)
CPC A61K 36/185 (2013.01) [A61K 31/05 (2013.01); A61K 31/12 (2013.01); A61K 31/16 (2013.01); A61K 31/164 (2013.01); A61K 31/165 (2013.01); A61K 31/19 (2013.01); A61K 31/4525 (2013.01); A61K 31/5685 (2013.01); A61K 31/658 (2023.05); A61K 36/068 (2013.01); A61K 36/28 (2013.01); A61K 36/9066 (2013.01)] 18 Claims
 
1. A method of treating arthritis in a human in need thereof consisting essentially of administering to the human in need thereof:
a) a cannabis extract which consists essentially of at least 5% of at least one of cannabigerol, cannabigerol acid, cannabigerovarin, and cannabigerovarin acid, wherein the cannabis extract lacks cannabidiol, cannabidolic acid, tetrahydrocannabinol, tetrahydrocannabinolic acid, cannabidivarin, cannabidivarin acid, tetrahydrocannabivarin, and tetrahydrocannabivarin acid;
b) resveratrol;
c) at least one of echinaea N-alkylamide and piperine; and
d) eugenol.